Compare Novo Nordisk A/S (NVO) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Tapestry, Inc. — how do they compare? Novo Nordisk A/S trades at $46.23 (market cap $207.85B), while Tapestry, Inc. trades at $153.64 (market cap $32.44B). The key difference: Novo Nordisk A/S is far larger — about 6.4× Tapestry, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | TPR | |
|---|---|---|
Market Cap | $207.85B | $32.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $164.78 |
52-Week Low | $35.29 | $95.69 |
Enterprise Value | $222.55B | $35.29B |
Dividend Yield | 3.81% | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
TPR trades at $164.78, up 1.49% with strong technical momentum and bullish moving averages. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $1.66 exceeding the $1.30 estimate. Analyst sentiment remains overwhelmingly positive with 31 buy ratings and a $190.33 consensus price target, representing 15.5% upside potential. Recent news highlights Tapestry's AI initiatives and strong brand momentum driving market share gains.
The outlook appears favorable given TPR's earnings beat streak and positive analyst coverage, though elevated valuation ratios (P/E 48.95, P/S 4.34) and recent net income margin compression from 12.23% to 2.61% warrant monitoring. Key risks include competitive pressures in luxury retail and potential macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
